Circ Arrhythm Electrophysiol

Slides:

Advertisements

Similar presentations

Efficacy and Safety of Vernakalant Hydrochloride Injection for the Treatment of Atrial Fibrillation After Valvular or Coronary Artery Bypass Surgery Peter.

Advertisements

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

1 Risk/Benefit Assessment Jeremy N. Ruskin, M.D. Director, Cardiac Arrhythmia Services Massachusetts General Hospital.

Atrial Fibrillation and Heart Failure Andrew A. Grace, MB, PhD, FRCP Heart Failure Clinics Volume 9, Issue 4, (October 2013) DOI: /j.hfc

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effects of Habitual Coffee Consumption on Cardiometabolic.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Duloxetine on Pain, Function, and Quality.

Cumulative Radiation Exposure and Cancer Risk Estimation in Children With Heart DiseaseCLINICAL PERSPECTIVE by Jason N. Johnson, Christoph P. Hornik, Jennifer.

Omega-3 Fatty Acid Blood Levels by H. Robert Superko, Scott M. Superko, Khurram Nasir, Arthur Agatston, and Brenda C. Garrett Circulation Volume 128(19):

Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them?Clinical Perspective by Peter J. Schwartz,

Copyright © 2003 American Medical Association. All rights reserved.

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated.

Circ Arrhythm Electrophysiol

New-onset Atrial Fibrillation Predicts Heart Failure Progression

by Michael D. Elliott, Ajoy Kapoor, Michele A. Parker, Dixon B

Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Emily C. O’Brien, PhD,

Circ Cardiovasc Qual Outcomes

by Adam J. Singer, Robert H

Circ Cardiovasc Interv

Circ Arrhythm Electrophysiol

Attenuation of the “White-Coat Effect” by Antihypertensive Treatment and Regression of Target Organ Damage by Gianfranco Parati, Luisa Ulian, Lorena Sampieri,

Gulf Survey of Atrial Fibrillation Events (Gulf SAFE)‏

Atrial Fibrillation and Mortality in Heart FailureClinical Perspective

Circ Arrhythm Electrophysiol

Circ Arrhythm Electrophysiol

Plasma Vitamin C, but Not Vitamin E, Is Associated With Reduced Risk of Heart Failure in Older MenClinical Perspective by Sasiwarang Goya Wannamethee,

Circ Cardiovasc Qual Outcomes

Evaluation of Left Ventricular Enlargement as a Marker of Early Disease in Familial Dilated CardiomyopathyClinical Perspective by Diane Fatkin, Thomas.

Circ Arrhythm Electrophysiol

Circ Arrhythm Electrophysiol

Circ Arrhythm Electrophysiol

Circ Cardiovasc Interv

by Thomas Monks, Martin Pitt, Ken Stein, and Martin James

Relative Distributions

Influence of Cardiac Surgeon Report Cards on Patient Referral by Cardiologists in New York State After 20 Years of Public Reporting by David L. Brown,

Contribution of Stroke to the Cochrane Stroke Group Trials Register

Circ Arrhythm Electrophysiol

Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary.

Slowing of ventricular rate (VR) associated with inferior vena cava–inferior atrial ganglionated plexus nerve activity (IVC-IAGPNA) discharge without right.

Circ Cardiovasc Qual Outcomes

Circ Arrhythm Electrophysiol

Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart FailureClinical Perspective by A. Rogier van der Velde, Lars Gullestad,

Risk of Heart Failure Among Postmenopausal WomenCLINICAL PERSPECTIVE

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

Body Mass Index and Heart Failure Among Patients With Type 2 Diabetes MellitusCLINICAL PERSPECTIVE by Weiqin Li, Peter T. Katzmarzyk, Ronald Horswell,

The Process of Rehabilitation and Discharge Planning in Stroke

Optimal Pacing for Right Ventricular and Biventricular Devices

Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.

James H. Liu, MD The American Journal of Medicine

Intermediate to Long-Term Results of Radiofrequency Modified Maze Procedure as an Adjunct to Open-Heart Surgery Willem P. Beukema, MD, Hauw T. Sie, MD,

Gaurav A. Upadhyay, MD, Jonathan S. Steinberg, MD Heart Rhythm

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

POINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management

Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.

Kidney Disease Among African Americans: A Population Perspective

The novel Kv1.5 channel blocker vernakalant for successful treatment of new-onset atrial fibrillation in a critically ill abdominal surgical patient

Copyright © 2013 Elsevier Inc. All rights reserved.

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Jerry Shapiro, Keith D. Kaufman

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

The American Journal of Medicine

Cumulative survival without events during 1 year of follow-up in patients treated with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril.

Figure 1 Annualized percentage brain volume change

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Rate and Rhythm Management Anne M. Gillis, MD, FRCPC, Atul Verma, MD, FRCPC, Mario.

Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.

Copyright © 2013 Elsevier Inc. All rights reserved.

Volume 82, Issue 11, Pages (December 2012)

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Survival free of atrial fibrillation after implantation of an implantable cardioverter defibrillator in our series (151 patients): overall population (solid.

Presentation transcript:

Circ Arrhythm Electrophysiol Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation After Cardiac SurgeryCLINICAL PERSPECTIVE by Peter R. Kowey, Paul Dorian, L. Brent Mitchell, Craig M. Pratt, Denis Roy, Peter J. Schwartz, Jerzy Sadowski, Dorota Sobczyk, Andrzej Bochenek, and Egon Toft Circ Arrhythm Electrophysiol Volume 2(6):652-659 December 1, 2009 Copyright © American Heart Association, Inc. All rights reserved.

Figure 1. Patient disposition Figure 1. Patient disposition. *One patient in the vernakalant group was adjudged by the Clinical Events Committee to be in SR before and after treatment. Figure 1. Patient disposition. *One patient in the vernakalant group was adjudged by the Clinical Events Committee to be in SR before and after treatment. Peter R. Kowey et al. Circ Arrhythm Electrophysiol. 2009;2:652-659 Copyright © American Heart Association, Inc. All rights reserved.

Figure 2. Success rates in the overall AF/AFL population and among patients with AF. Peter R. Kowey et al. Circ Arrhythm Electrophysiol. 2009;2:652-659 Copyright © American Heart Association, Inc. All rights reserved.

Figure 3. Cumulative responder percentage based on time after the start of treatment among patients with AF. Figure 3. Cumulative responder percentage based on time after the start of treatment among patients with AF. Peter R. Kowey et al. Circ Arrhythm Electrophysiol. 2009;2:652-659 Copyright © American Heart Association, Inc. All rights reserved.

Figure 4. Time course of changes from baseline in HR and QRS, QTcB, and QTcF for patients with AF/AFL given vernakalant compared with patients given placebo. Figure 4. Time course of changes from baseline in HR and QRS, QTcB, and QTcF for patients with AF/AFL given vernakalant compared with patients given placebo. Data (mean±SD) are shown for patients who remained in AF or AFL, except in A, which includes vernakalant-treated patients who demonstrated conversion to SR (wide error bars). Peter R. Kowey et al. Circ Arrhythm Electrophysiol. 2009;2:652-659 Copyright © American Heart Association, Inc. All rights reserved.